Eligibility of monoclonal antibody-based therapy for patients with severe asthma: a Canadian cross-sectional perspective

Based on immunologic phenotypes underlying asthma, use of monoclonal antibody based therapies is becoming the new standard of care for severe, corticosteroid refractory clinical symptoms. Patients may qualify ...

https://ift.tt/2PKwT6u